Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay

Cancer Journal from Scientific American

Volumn 4, Issue 5, 1998, Pages 316-323

  Pass, Helen A ^a   Schwarz, Susan L ^a   Wunderlich, John R ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; ELISPOT assay; Immunotherapy; Melanoma; T cells

Indexed keywords

CANCER VACCINE; PEPTIDE;

ADOPTIVE TRANSFER; ARTICLE; BINDING AFFINITY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VACCINATION;

CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0031716189     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 1997;27:81-86.
2. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by Tcells. Immunol Res 1997;16:313-339.
3. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-636.
4. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-182.
5. Rosenberg SA, YangJC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat Med 1998; 4:321-327.
6. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
7. Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
8. Gown AM, Vogel AM, Hoak D et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
9. Salgaller ML, Afshar A, Marincola FM et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-4979.
10. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A*0210 binding residues. J Immunol 1996;157:2539-2548.
11. Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-4757.
12. Czeridnsky CC, Nilsson L-A, Nygren H et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109-121.
13. Sedgwick JD, Holt PG. A solid-phase immuno-enzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol Methods 1982;57:301-309.
14. Scheibenbogen C, Lee KH, Stevanovic S et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELI-SPOT assay. Int J Cancer 1997;71:932-936.